TyrNovo Ltd. Report issue

For profit Phase 2
Founded: Herzliya Israel (2013)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2020
NCT04474470
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

TyrNovo Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

cetuximab (erbitux) (1 trial)

nt219 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 2)

Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2